Pharmaceuticals in Southeast Asia: reality and future prospects

Publication type Article
Status Published
Occupation: Research Fellow
Affiliation: Lomonosov Moscow State University, RANEPA
Address: Russian Federation, Moscow
Occupation: Student
Affiliation: Lomonosov Moscow State University
Address: 1, Leninskie Gory, Moscow, 119234
Journal nameProblemy Dalnego Vostoka
EditionIssue 5

The article is dedicated to the analysis of the pharmaceutical industry, one of the most actively developing sectors of the world economy, in the region of "new development" — Southeast Asia. It was found that at the present in the countries located in the region under consideration, there is a gradual shift away from the purely production stages of drug manufacturing in favour of an intersectoral pharmaceutical complex. There is a functional diversification of the pharmaceutical industry with deepening corporate specialization. However, a pronounced specialization in the production of a particular type of product is characteristic only for countries with high and medium levels of development of the pharmaceutical industry — Singapore, Malaysia and Indonesia. There is a gradual transformation of the territorial structure from monocentric — with a growth pole in the form of Singapore, to polycentric due to the growing contribution of Malaysia, Thailand and Indonesia. A distinctive feature of the pharmaceutical industry in Southeast Asia is the enclave type of development of its territorial structure at the country level. A significant part of production facilities and research laboratories is concentrated in one (capital), less often in two centres (the case of Indonesia — West and East Java and Vietnam with industrial cores in Hanoi and Ho Chi Minh City).

KeywordsPharmaceutical industry, medicines, pandemiс, location of production, Southeast Asia
Publication date18.10.2021
Number of characters50046
100 rub.
When subscribing to an article or issue, the user can download PDF, evaluate the publication or contact the author. Need to register.

Number of purchasers: 1, views: 907

Readers community rating: votes 0

1. Asawachintachit D. Opportunities and Investment Support Measures for Medical Industries in Thailand // Thailand Board of Investment. 4.07.2020. URL: (accessed: 03.06.2021).

2. Chapela V.A. Indonesia Pharmaceuticals // Global Business Report, 2015. URL: wp-content/uploads/2015/04/Indonesia_Pharmaceuticals2015_IE.pdf (accessed: 10.06.2021).

3. Falak A. Malaysia’s Healthcare Sector: A Rising Giant in ASEAN // ASEAN Briefing. 6.10.2020. URL: (accessed: 24.05.2021).

4. Jongudomsuk P. The Kingdom of Thailand Health System Review // Health Systems in Transition, 2015. Vol. 5. № 5.

5. Kheng Huat E. PhAMA Industry Fact Book 2012 // PhAMA, 2012. URL: (accessed: 10.05.2021).

6. Keat Chyuan C. PhAMA Industry Fact Book 2018 // PhAMA, 2018. URL: (accessed: 10.05.2021).

7. Medina A.F. Indonesia’s Healthcare Industry: Growing Opportunities for Foreign Investors // ASEAN Briefing. 30.07.2020. URL: (accessed: 10.06.2021).

8. Mercurio B., Kim D. Foreign Direct Investment in the Pharmaceutical Industry: Why Singapore and not Hong Kong // Asian Journal of Comparative Law, 2015. Vol. 1. № 2.

9. Nguyen J. Why Investors Should be Optimistic About Vietnam’s Healthcare Industry // Vietnam Briefing. 12.03.2021. URL: (accessed: 08.06.2021).

10. Rustiadi E., Pribadi D.O., Pravitasari A.E. Jabodetabek Megacity: From City Development Toward Urban Complex // Urban Development Challenges, Risks and Resilience in Asian Mega Cities / ed. R. B. Singh. Japan: Springer, 2015. DOI: 10.1007/978–4–431–55043–3_22.

11. Thuy N. Foreign investors continue to target Vietnam’s pharmaceutical industry // Hanoi Times. 3.01.2020. URL: (accessed: 09.06.2021).

Система Orphus